Close
FINDING CURES TOGETHER<sup>SM</sup>

Media Advisories

 

 

Cancer Research Catalyst Blog: Tinkering With CAR T Cells to Better Treat Patients18492979/3/2015 1:11:20 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx41False2015-09-03T13:00:00Z<div class="ExternalClassFDE7A9BD3E94496186E559FBF1CD506B"><p><em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a></em>, the blog of the American Association for Cancer Research (AACR), features a post, <a href="http&#58;//blog.aacr.org/advances-in-immunotherapy-fine-tuning-car-t-cells/" target="_blank">Advances in Immunotherapy&#58; Fine-tuning CAR T Cells</a>, from Srivani Ravoori, PhD, AACR senior science writer.&#160; </p><p>The post discusses two studies recently published in the AACR’s journal <em>Cancer Research</em>, about efforts to engineer CAR T cells to better target cancer cells and spare normal cells and make this type of immunotherapy applicable for patients with solid cancers.&#160; </p><p>These posts are part of the continuing mission of <em>Cancer </em><em>Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
Cancer Research Catalyst Blog: Bringing Cuba's Lung Cancer Vaccine to the States17925698/27/2015 1:15:28 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx40False2015-08-27T11:00:00Z<div class="ExternalClass684AAB874B564E66A93CD582FA671F54"><p><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), features a <a href="http&#58;//blog.aacr.org/bringing-cubas-lung-cancer-vaccine-to-the-states/" target="_blank">guest post</a> by Kelvin Lee, MD, professor and chair of the Department of Immunology at Roswell Park Cancer Institute (RPCI) in Buffalo, New York.&#160; </p><p>Lee discusses CimaVax, a lung cancer vaccine created by the Cuban Center for Molecular Immunology, and RPCI’s recent agreement with the biotechnology company to bring the vaccine to the United States for research and clinical testing.&#160; </p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
American Association for Cancer Research to Release New Cancer Progress Report and National Survey17814808/25/2015 4:12:51 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx39False2015-08-25T13:00:00Z<div class="ExternalClass1212522C238F40879A17BA5CCAFD4573"><p>WASHINGTON, D.C. — The American Association for Cancer Research (AACR) will announce the findings of the <em>AACR Cancer Progress Report 2015</em> on Wednesday, Sept. 16. Now in its fifth year, the report highlights how federally funded research can power progress against cancer.</p><p><a href="http&#58;//cancerprogressreport.org/Pages/default.aspx" target="_blank">See last year’s report</a>.</p><p>In conjunction with the report, the AACR will also be releasing the results of a new national survey on cancer and cancer research funding.</p><p>For more information, contact Julia Gunther at <a href="mailto&#58;julia.gunther@aacr.org">julia.gunther@aacr.org</a> or 267-250-5441, Jeff Molter at <a href="mailto&#58;jeff.molter@aacr.org">jeff.molter@aacr.org</a> or 267-210-3965, or Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155. </p></div>
American Association for Cancer Research CEO to Speak at Van Andel Research Institute on Team Science and Acceleration of Progress17589208/21/2015 8:17:25 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx38False2015-08-21T16:00:00Z<div class="ExternalClassC435DA9C4619434EAE83EDE6FC005AF0"><p>PHILADELPHIA — Margaret Foti, PhD, MD (hc), chief executive officer of the American Association for Cancer Research (AACR) will be delivering a lecture titled “Team Science and the Acceleration of Progress for Patient Benefit,” at an event hosted by the <a href="http&#58;//www.vai.org/" target="_blank">Van Andel Research Institute</a> in Grand Rapids, Michigan, Aug. 27.</p><p>The event, to begin at 4 p.m. ET, is free of charge and open to the public.&#160;<a href="http&#58;//www.eventbrite.com/e/dr-margaret-foti-lecture-registration-17765199189" target="_blank">Register here</a>.&#160;</p><p>For Foti’s bio, <a href="/AboutUs/Pages/officers-detail.aspx?ItemID=5">click here</a>.</p></div>
Cancer Research Catalyst Blog: New Clinical Trial Possibilities Now Open at NCI; a Physician-Scientist Aims to Understand Bladder Cancer in Children17518598/20/2015 4:15:59 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx37False2015-08-20T16:15:00Z<div class="ExternalClassD44BCF9824AF4DCDBBDE309C0691E67C"><p><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), features a <a href="http&#58;//blog.aacr.org/nci-match-trial-opens/" target="_blank">guest post</a> by Barbara A. Conley, MD, leader of the recently opened National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) trial, a precision medicine trial that will explore cancer treatments for patients based on molecular profiles of their tumors. </p><p>In addition, <a href="http&#58;//blog.aacr.org/andrew-l-hong-md-aacr-ccf-of-asco-young-investigator-translational-cancer-research-award/" target="_blank">read about</a> Andrew L. Hong, MD, who is approaching his research on pediatric bladder cancer from a unique “bedside-to-bed” perspective. Hong, an instructor of pediatrics at Harvard Medical School and Dana-Farber Cancer Institute, received funding for his research from the 2014 AACR-Conquer Cancer Foundation of ASCO Young Investigator Cancer Research Award.</p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
​​Leading Cancer Research Organizations to Host Inaugural International Cancer Immunotherapy Conference in New York, Sept. 16-1916482518/3/2015 1:54:56 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx36False2015-08-03T13:45:00Z<div class="ExternalClass3CB2D58973054D8F958081E9EA7B4DE5"><p>NEW YORK – The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept. 16-19, 2015.</p><p>Titled &quot;Translating Science Into Survival,&quot; the meeting will cover all areas of inquiry in cancer immunology and immunotherapy, including&#58; immune regulation of T-cell responsiveness, genomic methods for identifying tumor antigens, the tumor microenvironment, T-cell therapies, checkpoint blockade, biomarkers, combinations, and the microbiome. More than 60 talks by acknowledged leaders in these areas will be given.</p><p><a href="/Meetings/Pages/Program-Detail.aspx?EventItemID=54&amp;ItemID=149">See the full program</a>.</p><p>Registration is complimentary for credentialed news media. Members of the media can register using <a href="/Documents/15Immuno_RegForm.pdf" target="_blank">this form</a>. Return completed forms to Lauren Riley via email at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or via fax at 215-446-7291.</p><p>Public information officers at medical institutes and cancer centers can also register by contacting Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155.</p><p>Those following on social media can join the conversation on Twitter at <a href="https&#58;//twitter.com/hashtag/cicon15?f=tweets&amp;vertical=default&amp;src=hash" target="_blank">#cicon15</a>.</p><p>For more information, contact Julia Gunther at <a href="mailto&#58;julia.gunther@aacr.org">julia.gunther@aacr.org</a> or 267-250-5441, or Jeff Molter at <a href="mailto&#58;jeff.molter@aacr.org">jeff.molter@aacr.org</a> or 267-210-3965.</p></div>
Cancer Research Catalyst Blog: Discussing Cancer Causes and Fertility Issues Among Young Survivors15474107/16/2015 5:56:58 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx35False2015-07-16T17:00:00Z<div class="ExternalClass0F8AB91541DB4F96A1E17A6F8105E3B9"><p><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), features the guest post, <a href="http&#58;//blog.aacr.org/cancer-causes-inheritance-bad-luck-and-the-environment/" target="_blank">Cancer Causes&#58; Inheritance, ‘Bad Luck,’ and the Environment</a>, from William G. Nelson, MD, PhD, editor-in-chief of <em>Cancer Today</em>, the AACR’s quarterly magazine for cancer patients, survivors, and caregivers, and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The post was adapted from his column in the summer 2015 issue of <a href="http&#58;//www.cancertodaymag.org/SUmmer2015/Pages/Inheritance%2c-Bad-Luck-and-the-Environment-William-Nelson-Cancer.aspx" target="_blank"><em>Cancer Today</em></a>. </p><p>In addition, Marci Landsmann, editor of <em>Cancer Today</em>, provides a <a href="http&#58;//blog.aacr.org/young-adults-cancer-fertility-preservation/" target="_blank">post</a> discussing the progress and challenges associated with fertility preservation for young adults diagnosed with cancer.</p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> at&#160;and subscribe. </p></div>
New Blog Posts from the American Association for Cancer Research14679257/2/2015 7:17:56 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx34False2015-07-02T16:00:00Z<div class="ExternalClass844E45EA84074CA594A6E5226F30123A"><p><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), celebrated its first anniversary Wednesday, July 1. <a href="http&#58;//blog.aacr.org/cancer-research-catalyst-has-had-quite-a-first-year/" target="_blank">One hundred twenty-five posts later</a>, the <a href="http&#58;//philly.org/content.php?page=2012_Philadelphia_Pepperpot_Awards" target="_blank">award-winning blog </a>has been the perfect vehicle for accelerating the growth and spread of knowledge about cancer, communicating the latest happenings of the AACR, and providing helpful and interesting information to AACR members and the public. </p><p><strong>Posts this week&#58;</strong></p><p>Srivani Ravoori, PhD, AACR’s senior science writer, wrote a two-part series about drug resistance and the enigma of the epidermal growth factor receptor (EGFR). Read <a href="http&#58;//blog.aacr.org/overcoming-drug-resistance-the-egfr-enigma-part-1/" target="_blank">Part 1&#58; Overcoming Resistance to EGFR TKIs</a> and <a href="http&#58;//blog.aacr.org/overcoming-drug-resistance-the-egfr-enigma-part-2/" target="_blank">Part 2&#58; Overcoming Resistance to Anti-EGFR Antibody Therapies</a>. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe.&#160;&#160;</p></div>
Senate Labor-HHS-Education Appropriations Bill Proposes Largest Annual Increase for NIH Since 200382646/26/2015 2:13:21 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx33False2015-06-26T13:00:00ZAACR Commends Investment in Medical Research; Experts Available for Interviews<div class="ExternalClassC751054B33FD41B7A13B07A998B9AAC0"><p>WASHINGTON, D.C. — The American Association for Cancer Research (AACR) commends both the House and the Senate Appropriations Committees for making medical research a priority, and for recognizing the critical role that National Institutes of Health (NIH)-funded research plays in saving lives for those with cancer and other diseases. This funding is urgently needed if we are to continue to uncover scientific breakthroughs.</p><p>AACR President José Baselga, MD, PhD, is available for interviews. He is the physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center and is an internationally recognized physician and scientist who focuses on developing targeted therapies for breast cancer.</p><p>&quot;With advances in technology, there has never been a more exciting time in biomedical research against cancer and other diseases,&quot; Baselga said. &quot;While the NIH budget has stagnated for more than a decade, the Senate's proposal of a $2 billion increase in NIH funding for the Fiscal Year [FY] 2016 budget is a positive paradigm shift that reflects the importance of biomedical research, and overcomes the previous hurdles that have resulted from budget sequestration. This additional funding has the potential to open up new opportunities to cultivate junior scientists, to advance our understanding of genetics, and ultimately, to develop more effective treatments for patients with cancer and other diseases.&quot;</p><p>Jon Retzlaff, managing director of the AACR's Office of Science Policy and Government Affairs is also available for interviews to discuss the AACR's position, the political landscape, and future considerations that would enable this bill to be passed by the Senate.</p><p>&quot;This increase of approximately $2 billion is a significant step toward putting the NIH back on a path of sustained, predictable growth,&quot; said Retzlaff. &quot;The AACR applauds this bipartisan support for medical research, as well as specifically, Chairman Blunt's leadership and commitment to supporting the NIH.</p><p>&quot;However, we also recognize that this proposed increase for NIH is likely going to be dependent on a broader budget agreement to ease these restrictive spending caps that are in place for FY 2016, especially since Senate Democrats are threatening to filibuster all spending bills that adhere to the sequester budget caps, and the president has promised to veto any of the spending bills that arrive at his desk adhering to the budget caps. Therefore, this situation underscores the enormous importance for Democrats and Republicans to come together to ensure that the necessary additional resources are provided for both defense and nondefense discretionary programs.&quot;</p><p>Yesterday, the Senate Appropriations Committee approved the Labor, Health, and Human Services, and Education FY 2016 spending bill, which provides a $2 billion increase, 6.6 percent, in funding for the NIH— the largest increase since 2003. In addition, the committee recommended a 5 percent increase of $250 million in funding for the National Cancer Institute. These increases exceed those approved by the House Appropriations Committee June 24.</p><p>The markup of the Senate appropriations bill dovetails with the national discussion underway regarding the president's Precision Medicine Initiative, which received a $200 million funding commitment in the proposed bill. Baselga and other fellows of the AACR Academy participated in a Congressional briefing on precision medicine in partnership with the White House Office of Science and Technology June 17 to share their expertise and insight into how to best advance medical research, and emphasized the importance of investing in and harnessing the latest genomics technologies available to prevent or effectively treat cancer and many other diseases.</p></div>
Cancer Research Catalyst Blog: Powerhouse Cancer Experts Converge on Capitol Hill to Discuss Precision Medicine82636/19/2015 1:54:44 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx32False2015-06-17T19:00:00Z<div class="ExternalClass0A64A2C3C95042CC906408378B2EEDBB"><p><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), features a <a href="http&#58;//blog.aacr.org/fellows-of-the-aacr-academy-special-briefing-precision-medicine/" target="_blank">post about a congressional briefing held today</a> to stimulate additional support for President Obama’s Precision Medicine Initiative and to address the importance of biomedical funding. </p><p>The AACR held the special briefing, titled “<a href="/AdvocacyPolicy/GovernmentAffairs/Pages/fellows-of-the-AACR-academy.aspx">Saving Lives in the New Era of Precision Medicine</a>,” in conjunction with its fellows of the AACR Academy, Rep. André Carson, D-Ind., and Rep. David McKinley, R-W.Va.</p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>